Skip to content
Close
SEARCH
CONTACT US
CONTACT US

OUR SERVICES

We take a personalized and integrated approach to help our clients position their pipelines and companies for success offering a full range of development and commercialization services.

VIEW ALL SERVICES
PHASES
DISCOVERY
Uncover breakthrough
innovations during the drug
discovery phase.
CLINICAL DEVELOPMENT
Advance through clinical
development and health
authority review with confidence.
ALL STAGES
Benefit from our expertise
across all phases
of drug development.
PRECLINICAL
Navigate the critical
preclinical testing phase
with expert guidance.
COMMERCIALIZATION
Successfully bring your
product to market with
our commercialization support.
ALL SERVICES
Access comprehensive
services for every stage
of product development.

ABOUT US

We are Halloran, a life science consulting firm, partnering to enrich your product development and business growth. We propel your organization further; positively impacting the health and wellbeing of patients around the world.

LEARN MORE ABOUT US
EXPERTISE WITH PERSONALITY
OUR FOUNDER
Discover the visionary
leader driving Halloran's
success and innovation.
STRATEGIC PARTNERS
Meet our trusted
strategic partners who
enhance our capabilities.
WHY HALLORAN?
Explore the unique reasons
why clients choose
Halloran for their needs.
OUR TEAM
Get to know the dedicated
professionals who make
up the Halloran team.
CAREERS
Join our dynamic team
and advance your
career with Halloran.
CASE STUDIES
Learn Halloran’s unique
strategy and approach to address
the pressing needs of our clients.
hcg-service-hero-1

Insights From Halloran

Sheila GwizdakNov 25, 2024 12:00:00 AM2 min read

Disrupting the Clinical Trial Ecosystem

Start Reading
Sheila GwizdakNov 20, 2024 5:57:18 PM3 min read

Moving Through Clinical Development and Operations Obstacles on the Path to Commercialization

Start Reading
Halloran Consulting GroupOct 15, 2024 11:12:42 AM8 min read

Three Key Impacts in 2025: Fundraising, ICH E6(R3), and Policy

A Q&A featuring Tania Zieja, President of Halloran Consulting Group.
Start Reading
Lyn AgostinelliAug 21, 2024 12:45:00 PM2 min read

483 Issues to Sites – Indicators of Sponsor Oversight Effectiveness

A U.S. Food and Drug Administration (FDA) Form 483 is issued to a company’s management at ...
Start Reading
Halloran Consulting GroupAug 2, 2024 11:30:00 AM7 min read

How, Why, and When to Apply for an Orphan Drug Application

This article is written by Hema Balasubramanian and Mamta Puri-Lechner. In the rapidly ...
Start Reading
Halloran Consulting GroupJul 10, 2024 3:57:00 PM5 min read

Catching Up with Consulting — DIA 2024 Insights

This article is based on opinions and perceptions from the DIA 2024 Global Annual ...
Start Reading
Gail WinslowJul 3, 2024 4:00:00 PM4 min read

Generative AI-Driven Clinical Trials: Are We There Yet?

This article is based on the session titled, “Generative AI-Driven Clinical Trials: Myth ...
Start Reading
Gail WinslowJul 1, 2024 12:35:00 PM4 min read

Maximizing The Next 40 Years of The Orphan Drug Act 

This article is based on the session titled, “Sustainability of Rare Disease Drug ...
Start Reading
Rebecca Shorin, PMPJun 12, 2024 8:57:00 AM4 min read

Future of Clinical Trials: Forging New Pathways with Artificial Intelligence  

Biocom California’s first annual Converge Summit, recently held in South San Francisco, ...
Start Reading
Katie W McCarthyMay 15, 2024 12:15:00 PM4 min read

Investors Follow Teams: Leadership Considerations to Enable Success 

Developing a life science asset from early discovery through clinical development to ...
Start Reading
Load more posts